Format
Items per page
Sort by

Send to:

Choose Destination

Results: 8

1.

Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission.

Chéret A, Bacchus-Souffan C, Avettand-Fenoël V, Mélard A, Nembot G, Blanc C, Samri A, Sáez-Cirión A, Hocqueloux L, Lascoux-Combe C, Allavena C, Goujard C, Valantin MA, Leplatois A, Meyer L, Rouzioux C, Autran B; OPTIPRIM ANRS-147 Study Group.

J Antimicrob Chemother. 2015 Apr 21. pii: dkv084. [Epub ahead of print]

PMID:
25900157
2.

HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.

Frange P, Assoumou L, Descamps D, Chéret A, Goujard C, Tran L, Gousset M, Avettand-Fenoël V, Bocket L, Fafi-Kremer S, Guinard J, Morand-Joubert L, Nicot F, Plantier JC, Rogez S, Wirden M, Rouzioux C, Meyer L, Chaix ML; French ANRS CO 6 PRIMO Cohort, the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups; French ANRS CO 6 PRIMO Cohort the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups.

J Antimicrob Chemother. 2015 Feb 26. pii: dkv049. [Epub ahead of print]

PMID:
25885327
3.

Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.

Chéret A, Nembot G, Mélard A, Lascoux C, Slama L, Miailhes P, Yeni P, Abel S, Avettand-Fenoel V, Venet A, Chaix ML, Molina JM, Katlama C, Goujard C, Tamalet C, Raffi F, Lafeuillade A, Reynes J, Ravaux I, Hoën B, Delfraissy JF, Meyer L, Rouzioux C; OPTIPRIM ANRS Study Group.

Lancet Infect Dis. 2015 Apr;15(4):387-96. doi: 10.1016/S1473-3099(15)70021-6. Epub 2015 Feb 18.

PMID:
25701561
4.

COL05-02 : Résultats de l'essai OPTIPRIM-ANRS 147.

Chéret A, Mélard A, Nembot G, Lascoux C, Reynes J, Meyer L, Rouzioux C.

Med Mal Infect. 2014 Jun;44(6 Suppl):9. doi: 10.1016/S0399-077X(14)70060-5. French. No abstract available.

PMID:
24994147
5.

A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection.

Bacchus C, Cheret A, Avettand-Fenoël V, Nembot G, Mélard A, Blanc C, Lascoux-Combe C, Slama L, Allegre T, Allavena C, Yazdanpanah Y, Duvivier C, Katlama C, Goujard C, Seksik BC, Leplatois A, Molina JM, Meyer L, Autran B, Rouzioux C; OPTIPRIM ANRS 147 study group.

PLoS One. 2013 May 14;8(5):e64219. doi: 10.1371/journal.pone.0064219. Print 2013.

6.

CD8 T-cells from most HIV-infected patients lack ex vivo HIV-suppressive capacity during acute and early infection.

Lécuroux C, Girault I, Chéret A, Versmisse P, Nembot G, Meyer L, Rouzioux C, Pancino G, Venet A, Sáez-Cirión A; ANRS 147 OPTIPRIM clinical trial.

PLoS One. 2013;8(3):e59767. doi: 10.1371/journal.pone.0059767. Epub 2013 Mar 29.

7.

Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.

Parienti JJ, Barrail-Tran A, Duval X, Nembot G, Descamps D, Vigan M, Vrijens B, Panhard X, Taburet AM, Mentré F, Goujard C.

Antimicrob Agents Chemother. 2013 May;57(5):2265-71. doi: 10.1128/AAC.02605-12. Epub 2013 Mar 4.

8.

Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

Savic RM, Barrail-Tran A, Duval X, Nembot G, Panhard X, Descamps D, Verstuyft C, Vrijens B, Taburet AM, Goujard C, Mentré F; ANRS 134–COPHAR 3 Study Group.

Clin Pharmacol Ther. 2012 Nov;92(5):575-83. doi: 10.1038/clpt.2012.137. Epub 2012 Oct 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk